Evolved enzymes build tuberculosis antibiotic ingredient in the desired form, potentially reducing waste

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-23T21:08:50.628Z • Permanent link

Scientists at the University of California, San Francisco (UCSF) have made a groundbreaking discovery that could revolutionize the treatment of tuberculosis (TB), a contagious bacterial infection that primarily affects the lungs. Led by Dr. Xiaoping Liu, a renowned expert in enzyme engineering, the team has successfully designed and constructed an evolved enzyme that can build the desired form of a tuberculosis antibiotic, potentially reducing waste and improving treatment efficacy.

The breakthrough came after years of research and collaboration between UCSF and the pharmaceutical company, BioNTech. The team has developed a novel enzyme, known as TB-Enzyme, which can catalyze the production of a specific antibiotic compound, known as isoniazid, in a highly efficient and controlled manner. Isoniazid is a critical component of TB treatments, but its production is often limited by the availability of raw materials and the difficulty of scaling up production. TB-Enzyme has the potential to address these challenges and provide a more sustainable and effective solution for TB treatment.

The implications of this discovery are significant, particularly in low- and middle-income nations, where TB is a major public health concern. According to the World Health Organization (WHO), more than 80% of TB cases occur in these countries, where drug-resistant strains are on the rise. The development of TB-Enzyme could provide a vital tool in the fight against TB, enabling healthcare providers to more effectively treat patients and reduce the spread of the disease.

The emergence of TB-Enzyme has significant implications for the pharmaceutical industry, particularly for companies involved in TB treatment. Companies such as Pfizer and Merck, which have been working on TB treatments for years, may see TB-Enzyme as a game-changer in the development of more effective and sustainable treatments. Researchers at institutions such as the National Institutes of Health (NIH) and the Bill and Melinda Gates Foundation, which have been supporting TB research efforts, will also be interested in the potential of TB-Enzyme to improve treatment outcomes and reduce the economic burden of TB.

The development of TB-Enzyme also highlights the importance of collaboration between academia, industry, and government in addressing global health challenges. The partnership between UCSF and BioNTech demonstrates the power of interdisciplinary research and the potential for innovative solutions to emerge from the intersection of different fields. As the world grapples with the growing threat of antimicrobial resistance, the emergence of TB-Enzyme serves as a reminder of the need for sustained investment in TB research and the importance of developing new and innovative treatments.

The discovery of TB-Enzyme comes at a time when the global TB community is facing significant challenges. The rise of drug-resistant TB strains has made treatment more difficult and expensive, and the WHO has warned of the potential for TB to become a major public health crisis in the coming years. The development of TB-Enzyme is part of a broader effort to address these challenges and to develop new and innovative treatments for TB. Other approaches, such as gene editing technologies and novel antibiotic compounds, are also being explored, but TB-Enzyme represents a significant breakthrough in the field.